Clinical Characteristics and Prognosis of Hospitalized ...



Supplemental Table 2　Medication use other than ACE inhibitors and ARBs among different ARB subgroups

| |Candesartan |Valsartan |Losartan |Others |P value |

| |(n=143) |(n=113) |(n=83) |(n=33) | |

|　β-blocker |65.7 |69.0 |65.1 |72.7 |0.816 |

|　Diuretic |84.6 |89.4 |92.8 |87.9 |0.311 |

|Spironolactone |44.8 |53.1 |59.0 |30.3 |0.021 |

|Digitalis |32.2 |19.5 |26.5 |33.3 |0.119 |

|Calcium-channel blocker |11.9 |21.2 |13.3 |30.3 |0.027 |

|　Antiarrhythmic |18.2 |16.8 |26.5 |6.1 |0.068 |

|　Aspirin |47.6 |56.6 |48.2 |48.5 |0.488 |

| Warfarin |44.8 |34.5 |43.4 |27.3 |0.145 |

|　Statin |26.6 |22.1 |22.9 |12.1 |0.352 |

ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download